Indian Biotech Sector Surges to US $4 bn

Bangalore: The Indian Biotech industry gained growth momentum by recording the fastest growth in the last five years to touch revenues of USD four billion or Rs 18,399.34 crore in 2010-11, a survey has said.

Of this, the biotech industry contributed Rs 17,249.34 crore while the life science education market made-up for the remaining Rs 1,150 crore,according to the 9th annual BioSpectrum-Association of Biotechnology Led Enterprises (ABLE) survey.

The biotech industry, without the life sciences education component, recorded revenue growth of 21.5 per cent over 2009-10 revenues of Rs 14,199 crore.

The top 10 South based companies, led by Biocon, contributed USD one billion in revenues at Rs 4816 crore.

The contribution of BioPharma, BioServices, BioAgri, Bioindustrials and Bioinformatics verticals was Rs 10645 crore, Rs 3245.97 crore, Rs 2480 crore, Rs 626 crore and Rs 252 crore respectively.

The BioPharma vertical contributed almost two-fifth of the industry revenues, followed by BioServices with 18.82 per cent and BioAgri with 14.38 per cent contribution. Bioindustrials and BioInformatics made up the rest of the industry revenue.

The fastest growing sector, BioAgri, has increased its market share in the last five years ? from less than five per cent to over 14 per cent of the 2011 industry revenue.

BioInformatics companies have increased exports business revenue in 2010-11 to claim 42 per cent segment share with more focus on customers in the US and Europe.

Growth of biologics in the domestic market gave an eight per cent boost to the BioPharma segment which clocked about 21 per cent growth in 2010-11, the survey revealed.

Cheaper biochemical alternatives dragged down the growth of Bioindustrial segment. It grew at 10.98 per cent in 2010-11, a drop of 7.01 per cent over previous year?s growth.

The Biotech industry derived 51 per cent of the overall revenues–Rs 8,852.34 crore?from exports.

Biocon retained its top slot of number one company in the overall revenue ranking, growing at a healthy 26 per cent. Of the Top 20 companies, Shantha Biotech and Jubilant Life Sciences faced a drop in revenue while Ankur Seeds posted a spectacular growth in revenues.

Nearly 175 Biotech companies in South India contributed to 44 per cent of the total revenues in 2010-11, up from 39 per cent in 2009-10. Western Indian states with 139 companies contributed to nearly 43.60 per cent.

In terms of the number of companies, south continued its dominance with 175 companies, while west has 139 companies.

North India with 48 companies was the next big contributor.

Biocon retained the number one position with revenues of Rs 1083 crore, followed by Serum Institute of India (Rs 1041 crore) from Pune, New Delhi based Panacea Biotec (Rs 928.41 crore), Nuziveedu Seeds from Hyderabad (Rs 610 crore), and Reliance Life Sciences (Rs 490 crore). Serum Institute recovered from its previous year?s slump, thanks to the robust sales of the newly introduced Swine flu vaccine.